AIM
SUPN icon

Alambic Investment Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Alambic Investment Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,409
Closed -$346K – 392
2018
Q4 		$346K Buy
+10,409
New +$448K 0.15% 202
2018
Q2 		– Sell
-5,550
Closed -$254K – 445
2018
Q1 		$254K Buy
+5,550
New +$232K 0.04% 390

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Alambic Investment Management's SUPN Position: Q1 2019 in Review

Alambic Investment Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2019, closing a stake of 10,409 shares — an estimated $346K sold.

Alambic Investment Management first reported a position in SUPN in Q1 2018 and held it in 2 quarters. The position peaked at $346K in Q4 2018. 289 funds tracked by Wall St. Rank hold SUPN as of Q1 2019.

  • Alambic Investment Management reported no remaining Supernus Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Alambic Investment Management sold 10,409 Supernus Pharmaceuticals shares in Q1 2019, an estimated $346K.
  • Alambic Investment Management first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Alambic Investment Management's Supernus Pharmaceuticals position peaked at $346K in Q4 2018.
  • 289 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2019.

Based on Alambic Investment Management's 13F filing for Q1 2019, filed 9 May 2019.